



L Number	Hits	Search Text	DB	Time stamp
1	602	((564/169) or (514/621)).CCLS.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/09 12:29

da1



17a1



chain nodes :

7 8 9 10 11 12 13 14 17 21

ring nodes :

1 2 3 4 5 6

chain bonds :

4-7 5-8 7-9 7-10 8-11 11-12 12-13 12-14 14-21

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

5-8 7-9 7-10 8-11 12-13 12-14 14-21

exact bonds :

4-7 11-12

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G1:C,O,N

G2:OH,Hy, [\*1]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom  
11:CLASS 12:CLASS 13:CLASS 14:CLASS 17:Atom 21:CLASS

Generic attributes :

17:  
Saturation : Unsaturated

Element Count :

Node 17: Limited  
C,C6-14

=&gt;

Uploading 10070084.str


L1        STRUCTURE UPLOADED

=&gt; d l1

L1 HAS NO ANSWERS

L1        STR

Cb 1



G1 C,O,N

G2 OH,Hy,[@1]

Structure attributes must be viewed using STN Express query preparation.

=&gt; s l1 sss sam

SAMPLE SEARCH INITIATED 17:46:33 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 533 TO ITERATE

100.0% PROCESSED 533 ITERATIONS

25 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 9275 TO 12045

PROJECTED ANSWERS: 200 TO 800

L2 25 SEA SSS SAM L1

=&gt; s l1 sss ful

FULL SEARCH INITIATED 17:47:00 FILE 'REGISTRY'

10/070,084

FULL SCREEN SEARCH COMPLETED - 10323 TO ITERATE

100.0% PROCESSED 10323 ITERATIONS  
SEARCH TIME: 00.00.01

439 ANSWERS


L3 439 SEA SSS FUL L1

=> s 13

L4 16 L3

=> d 14 1-16 bib,ab,hitstr

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2002:726092 CAPLUS  
 DN 138:187483  
 TI Syntheses of [carbonyl- $^{11}\text{C}$ ]2-(2-benzoylphenoxy)-N-phenylacetamide from  
 [11C]carbon monoxide by the Suzuki and the Stille reactions  
 AU Nader, M. W.; Oberdorfer, F.  
 CS LKH Klagenfurt, PET-Zentrum NMSE, ARGOS Zyklotron Betriebs-Ges.m.b.H & Co.  
 KEG, Klagenfurt, A-9026, Austria  
 SO Applied Radiation and Isotopes (2002), 57(5), 681-685  
 CODEN: ARISEF; ISSN: 0969-8043  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 138:187483  
 AB Syntheses Ph11COC6H4OCH2CONHPh-2, a radiolabeled inhibitor of human  
 immunodeficiency virus type 1 (HIV 1) reverse transcriptase, were achieved  
 by applying palladium-mediated cross-coupling reactions with insertion of  
 [11C]carbon monoxide. A comparison was made of the Stille and Suzuki  
 methods, using PhSnMe3 or PhB(OH)2, resp., as coupling reagent. The  
 Suzuki variant gave a much higher amt. of [11C]CO radioactivity trapped in  
 the reaction mixt., but a significant loss of product occurred due to  
 adsorption phenomena on the potassium carbonate present in the  
 heterogeneous reaction mixt. The labeled product was isolated in only 20%  
 yield (based on trapped [11C]CO, not cor. for decay). According to  
 Stille, the reaction provided a product that could be isolated more easily  
 but it did not increase the final yield of the target compd. due to a low  
 trapping efficiency for [11C]CO. Both methods were performed in an  
 overall synthesis time of 30 min, starting from [11C]CO2, and gave a  
 product with a specific radioactivity of at least 30 GBq/.mu.mol. The  
 Stille method as well as the Suzuki reaction allowed the synthesis of a  
 radiochem. pure product in aq. acetonitrile.  
 IT **324743-12-6P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of [carbonyl- $^{11}\text{C}$ ]2-(2-benzoylphenoxy)-N-phenylacetamide from  
 [11C]carbon monoxide by the Suzuki and the Stille reactions)  
 RN 324743-12-6 CAPLUS  
 CN Acetamide, 2-[2-(benzoyl-carbonyl- $^{11}\text{C}$ )phenoxy]-N-phenyl- (9CI) (CA INDEX  
 NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:695941 CAPLUS

DN 137:232453

TI Preparation of substituted benzophenones as inhibitors of reverse transcriptase

IN Chan, Joseph Howing

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 163 pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070470	A2	20020912	WO 2002-US6037	20020228
	WO 2002070470	A3	20030306		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG EP 1363877 A2 20031126 EP 2002-723265 20020228 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR NO 2003003857 A 20031027 NO 2003-3857 20030901				
PRAI	US 2001-272953P	P	20010302		
	WO 2002-US6037	W	20020228		
OS	MARPAT 137:232453				
AB	Title compds. I [R1 = .gtoreq.1 substituent chosen from halo, CF3, alkyl, aminoalkyl, alkoxy, CN, NO2, NH2, thioalkoxy, etc.; R2 = H, halo, alkyl, NO2, NH2, alkylamino, CF3, alkoxy; R3 = OH, halo, CF3, NO2, alkyl; R4 = sulfonamido, sulfonylimino, etc.;] were prepd. For instance, 3,5-dichlorobromobenzene was metalated (MTBE, n-BuLi, -50.degree.) and acylated with the N,2-dimethoxy-N-methyl-5-chlorobenzamide and the resulting benzophenone converted to II. II was converted to III in 5 steps. Polymorphic forms of sodium, choline, calcium, magnesium, ethanolamine and triethylamine salts of III were prepd. and characterized. Oral bioavailability and soly. parameters were detd. for III and polymorphic salt forms thereof. Compds. of the present invention have anti-HIV activity and deliver compds. that have anti- HIV activity in the range IC50 = 1-1000 nM against wild type and mutant viruses.				
IT	329936-49-4P 329939-64-2P 329940-99-0P 457636-22-5P 457636-23-6P 457636-28-1P 457636-29-2P 457636-30-5P 457636-31-6P 457636-32-7P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; prepn. of substituted benzophenones as inhibitors of reverse transcriptase)				
RN	329936-49-4 CAPLUS				
CN	Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)				




RN 329939-64-2 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329940-99-0 CAPLUS


CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 457636-22-5 CAPLUS


CN Acetamide, N-[4-[[[(bromoacetyl)amino]sulfonyl]-2-methylphenyl]-2-[4-chloro-

2-(3-cyano-5-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 457636-23-6 CAPLUS


CN Acetamide, N-[4-[(bromoacetyl)amino]sulfonyl]-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 457636-28-1 CAPLUS


CN Carbamic acid, [(1S,2S)-1-[[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]amino]carbonyl]-2-methylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457636-29-2 CAPLUS


CN Carbamic acid, [1-[[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 457636-30-5 CAPLUS

CN Carbamic acid, [(1S)-1-[[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]amino]carbonyl]-3-methylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457636-31-6 CAPLUS


CN Carbamic acid, [(1R)-2-[[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457636-32-7 CAPLUS

CN Carbamic acid, [2-[[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 457636-12-3P 457636-14-5P 457636-15-6P  
457636-16-7P 457636-17-8P 457636-18-9P

RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(prodrug reverse-transcriptase inhibitor; prepn. of substituted benzophenones as inhibitors of reverse transcriptase)

RN 457636-12-3 CAPLUS

CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monopotassium salt (9CI) (CA INDEX NAME)



● K


RN 457636-14-5 CAPLUS

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]propanamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 457636-13-4


CMF C26 H20 Cl2 N3 O6 S



CM 2


CRN 62-49-7

CMF C5 H14 N O



RN 457636-15-6 CAPLUS


CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, calcium salt (2:1) (9CI) (CA INDEX NAME)



● 1/2 Ca

RN 457636-16-7 CAPLUS

CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, magnesium salt (2:1) (9CI) (CA INDEX NAME)




● 1/2 Mg

RN 457636-17-8 CAPLUS  
 CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, compd. with 2-aminoethanol (1:1) (9CI)  
 (CA INDEX NAME)

CM 1

CRN 457635-65-3  
 CMF C26 H21 Cl2 N3 O6 S



CM 2

CRN 141-43-5  
 CMF C2 H7 N O

H<sub>2</sub>N-CH<sub>2</sub>-CH<sub>2</sub>-OH


RN 457636-18-9 CAPLUS  
 CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]a

mino]-3-methylphenyl]sulfonyl]-, compd. with N,N-diethylethanamine (1:1)  
(9CI) (CA INDEX NAME)

CM 1

CRN 457635-65-3


CMF C26 H21 Cl2 N3 O6 S



CM 2

CRN 121-44-8

CMF C6 H15 N



IT 457635-45-9P 457635-46-0P 457635-47-1P  
 457635-48-2P 457635-49-3P 457635-51-7P  
 457635-52-8P 457635-53-9P 457635-54-0P  
 457635-55-1P 457635-56-2P 457635-57-3P  
 457635-58-4P 457635-59-5P 457635-60-8P  
 457635-61-9P 457635-62-0P 457635-63-1P  
 457635-64-2P 457635-65-3P 457635-66-4P  
 457635-67-5P 457635-68-6P 457635-69-7P  
 457635-70-0P 457635-71-1P 457635-72-2P  
 457635-73-3P 457635-74-4P 457635-75-5P  
 457635-76-6P 457635-77-7P 457635-78-8P  
 457635-79-9P 457635-80-2P 457635-81-3P  
 457635-82-4P 457635-83-5P 457635-84-6P  
 457635-85-7P 457635-86-8P 457635-87-9P  
 457635-88-0P 457635-89-1P 457635-90-4P  
 457635-91-5P 457635-92-6P 457635-93-7P  
 457635-94-8P 457635-95-9P 457635-96-0P  
 457635-97-1P 457635-98-2P 457635-99-3P  
 457636-00-9P 457636-01-0P 457636-02-1P  
 457636-03-2P 457636-04-3P 457636-05-4P  
 457636-06-5P 457636-07-6P 457636-08-7P  
 457636-09-8P 457636-10-1P 457636-11-2P


**457643-46-8P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prodrug reverse-transcriptase inhibitor; prepn. of substituted benzophenones as inhibitors of reverse transcriptase)

RN 457635-45-9 CAPLUS


CN Acetamide, N-[4-[(acetylamino)sulfonyl]-2-methylphenyl]-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457635-46-0 CAPLUS

CN Acetamide, N-[4-[(acetylamino)sulfonyl]-2-methylphenyl]-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 457635-47-1 CAPLUS


CN Propanamide, N-[[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-2-methyl-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457635-48-2 CAPLUS

CN Propanamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 457635-49-3 CAPLUS


CN Propanamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 457635-51-7 CAPLUS


CN Propanamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 457635-52-8 CAPLUS

CN 1-Pyrrolidineacetamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 457635-53-9 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 457635-54-0 CAPLUS  
 CN 1-Piperidineacetamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457635-55-1 CAPLUS

CN 1-Piperidineacetamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457635-56-2 CAPLUS


CN 4-Morpholineacetamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457635-57-3 CAPLUS

CN 4-Morpholineacetamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457635-58-4 CAPLUS


CN Propanamide, N-[[4-[[[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457635-59-5 CAPLUS

CN Propanamide, N-[[4-[[[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457635-60-8 CAPLUS


CN Propanamide, N-[[4-[[[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-2-methyl-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457635-61-9 CAPLUS

CN Propanamide, N-[[4-[[[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 457635-62-0 CAPLUS


CN Butanamide, N-[[4-[[[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-3-methyl-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457635-63-1 CAPLUS

CN Butanamide, N-[[4-[[[4-chloro-2-{3-cyano-5-(trifluoromethyl)benzoyl}phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 457635-64-2 CAPLUS


CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457635-65-3 CAPLUS

CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457635-66-4 CAPLUS


CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-2-methyl-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457635-67-5 CAPLUS

CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 457635-68-6 CAPLUS


CN Butanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-3-methyl-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 457635-69-7 CAPLUS


CN Butanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 457635-70-0 CAPLUS

CN 1-Pyrrolidineacetamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 457635-71-1 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 457635-72-2 CAPLUS  
 CN Butanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457635-73-3 CAPLUS

CN Butanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457635-74-4 CAPLUS


CN Pentanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457635-75-5 CAPLUS

CN Pentanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457635-76-6 CAPLUS


CN Carbamic acid, [[4-[[[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, 2-methylpropyl ester, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457635-77-7 CAPLUS

CN Carbamic acid, [[4-[[[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)



RN 457635-78-8 CAPLUS


CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, 2-methylpropyl ester, monosodium salt  
(9CI) (CA INDEX NAME)



● Na


RN 457635-79-9 CAPLUS

CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 457635-80-2 CAPLUS


CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, 2-methoxyethyl ester, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457635-81-3 CAPLUS

CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)



RN 457635-82-4 CAPLUS


CN Acetamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-2-methoxy-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457635-83-5 CAPLUS

CN Acetamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 457635-84-6 CAPLUS


CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[[[ethoxymethyl]amino]sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 457635-85-7 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[[[2-(2-methoxyethoxy)ethoxy]methyl]amino]sulfonyl]-2-methylphenyl]-  
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH<sub>2</sub>—OMe

RN 457635-86-8 CAPLUS

CN 4-Morpholineacetamide, N-[[4-[[[4-chloro-2-[3-fluoro-5-


(trifluoromethyl)benzoyl]phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 457635-87-9 CAPLUS


CN Pentanamide, 2-amino-N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-3-methyl-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457635-88-0 CAPLUS


CN Butanamide, 2-amino-N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-3-methyl-, (9CI) (CA INDEX NAME)



RN 457635-89-1 CAPLUS

CN Pentanamide, 2-amino-N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-4-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457635-90-4 CAPLUS


CN Propanamide, 2-amino-N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 457635-91-5 CAPLUS

CN Acetamide, N-[4-[[[(aminoacetyl)amino]sulfonyl]-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 457635-92-6 CAPLUS


CN Acetamide, N-[4-[[[(aminoacetyl)amino]sulfonyl]-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 457635-93-7 CAPLUS


CN Acetamide, N-[4-[(acetylamino)sulfonyl]-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 457635-94-8 CAPLUS


CN Acetamide, N-[4-[(acetylamino)sulfonyl]-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 457635-95-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-1-methyl-, monosodium salt, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 457635-96-0 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-1-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 457635-97-1 CAPLUS

CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 457635-98-2 CAPLUS


CN Acetamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 457635-99-3 CAPLUS

CN Hexanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-N-methyl- (9CI) (CA INDEX NAME)


ino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457636-00-9 CAPLUS

CN Hexanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457636-01-0 CAPLUS


CN Heptanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457636-02-1 CAPLUS

CN Heptanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457636-03-2 CAPLUS


CN Octanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457636-04-3 CAPLUS

CN Octanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457636-05-4 CAPLUS


CN Nonanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457636-06-5 CAPLUS

CN Nonanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457636-07-6 CAPLUS


CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, 1-methylethyl ester, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457636-08-7 CAPLUS

CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 457636-09-8 CAPLUS


CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, ethyl ester, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 457636-10-1 CAPLUS

CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 457636-11-2 CAPLUS


CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, methyl ester, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 457643-46-8 CAPLUS


CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2001:185739 CAPLUS  
 DN 134:237301  
 TI Preparation of benzophenones and phenyl heteroaryl ketones as inhibitors  
 of reverse transcriptase  
 IN Andrews, Clarence Webster; Chan, Joseph Howing; Freeman, George Andrew;  
 Romines, Karen Rene; Tidwell, Jeffrey H.  
 PA Glaxo Group Limited, UK; Pianetti, Pascal Maurice Charles  
 SO PCT Int. Appl., 436 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


*App. PCT*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001017982	A1	20010315	WO 2000-EP8487	20000831
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000013771	A	20020514	BR 2000-13771	20000831
	EP 1208091	A1	20020529	EP 2000-967637	20000831
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003510252	T2	20030318	JP 2001-521729	20000831
	NO 2002001042	A	20020430	NO 2002-1042	20020301
PRAI	GB 1999-20872	A	19990904 ✓		
	WO 2000-EP8487	W	20000831		
OS	MARPAT 134:237301				
AB	The title compds. [I; X = C, O, N; R1 = alkyl, cycloalkyl, (un)substituted aryl, etc.; R2 = H, halo, alkyl; R3, R4 = H, OH, (un)substituted heterocyclyl, etc.; R5 = H, halo, alkyl, etc.], useful in the treatment of HIV infections, were prepd. E.g., a 4-step synthesis of the ketone II which showed IC50 of between 101 nM and 1,000 nM against HIV-1 in MT4 cell assay, was described.				
IT	<b>329937-09-9P 329937-13-5P 329939-06-2P</b> <b>329939-33-5P 329939-35-7P</b> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of benzophenones and Ph heteroaryl ketones as inhibitors of reverse transcriptase)				
RN	329937-09-9 CAPLUS				
CN	Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-6-quinoxaliny- (9CI) (CA INDEX NAME)				




RN 329937-13-5 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-nitrophenoxy)-N-phenyl- (9CI) (CA INDEX NAME)



RN 329939-06-2 CAPLUS


CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-(2-chloro-4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



564/169


RN 329939-33-5 CAPLUS

CN Acetamide, 2-[2-(2-bromobenzoyl)-4-chlorophenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 329939-35-7 CAPLUS

CN Acetamide, 2-[2-(4-bromobenzoyl)-4-chlorophenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)



IT 329935-96-8P 329935-98-0P 329936-00-7P  
 329936-02-9P 329936-04-1P 329936-06-3P  
 329936-08-5P 329936-11-0P 329936-13-2P  
 329936-15-4P 329936-17-6P 329936-19-8P  
 329936-21-2P 329936-23-4P 329936-25-6P  
 329936-27-8P 329936-29-0P 329936-31-4P  
 329936-33-6P 329936-35-8P 329936-37-0P  
 329936-39-2P 329936-41-6P 329936-43-8P  
 329936-45-0P 329936-47-2P 329936-49-4P  
 329936-51-8P 329936-53-0P 329936-55-2P  
 329936-57-4P 329936-59-6P 329936-61-0P  
 329936-63-2P 329936-65-4P 329936-67-6P  
 329936-69-8P 329936-71-2P 329936-73-4P  
 329936-75-6P 329936-77-8P 329936-79-0P  
 329936-81-4P 329936-83-6P 329936-85-8P  
 329936-87-0P 329936-89-2P 329936-91-6P  
 329936-93-8P 329936-95-0P 329936-97-2P  
 329936-99-4P 329937-01-1P 329937-03-3P  
 329937-05-5P 329937-07-7P 329937-11-3P  
 329937-15-7P 329937-17-9P 329937-19-1P  
 329937-21-5P 329937-23-7P 329937-25-9P  
 329937-27-1P 329937-29-3P 329937-31-7P  
 329937-33-9P 329937-35-1P 329937-37-3P  
 329937-39-5P 329937-40-8P 329937-42-0P  
 329937-44-2P 329937-45-3P 329937-48-6P  
 329937-50-0P 329937-52-2P 329937-54-4P  
 329937-56-6P 329937-58-8P 329937-60-2P  
 329937-61-3P 329937-63-5P 329937-65-7P  
 329937-67-9P 329937-69-1P 329937-71-5P


329937-73-7P 329937-75-9P 329937-76-0P  
 329937-78-2P 329937-80-6P 329937-83-9P  
 329937-86-2P 329937-89-5P 329937-91-9P  
 329937-93-1P 329937-95-3P 329937-97-5P  
 329937-98-6P 329938-00-3P 329938-02-5P  
 329938-04-7P 329938-06-9P 329938-08-1P  
 329938-10-5P 329938-12-7P 329938-14-9P  
 329938-16-1P 329938-20-7P 329938-26-3P  
 329938-28-5P 329938-30-9P 329938-32-1P  
 329938-34-3P 329938-36-5P 329938-38-7P  
 329938-40-1P 329938-42-3P 329938-45-6P  
 329938-47-8P 329938-48-9P 329938-50-3P  
 329938-52-5P 329938-54-7P 329938-56-9P  
 329938-57-0P 329938-58-1P 329938-60-5P  
 329938-62-7P 329938-63-8P 329938-65-0P  
 329938-66-1P 329938-68-3P 329938-70-7P  
 329938-72-9P 329938-74-1P 329938-76-3P  
 329938-78-5P 329938-80-9P 329938-82-1P  
 329938-84-3P 329938-88-7P 329938-90-1P  
 329938-91-2P 329938-94-5P 329938-95-6P  
 329938-96-7P 329938-98-9P 329939-00-6P  
 329939-02-8P 329939-04-0P 329939-08-4P  
 329939-10-8P 329939-12-0P 329939-14-2P  
 329939-16-4P 329939-18-6P 329939-20-0P  
 329939-22-2P 329939-24-4P 329939-26-6P  
 329939-28-8P 329939-29-9P 329939-31-3P  
 329939-32-4P 329939-37-9P 329939-39-1P  
 329939-41-5P 329939-44-8P 329939-45-9P  
 329939-48-2P 329939-50-6P 329939-52-8P  
 329939-54-0P 329939-55-1P 329939-57-3P  
 329939-58-4P 329939-59-5P 329939-61-9P  
 329939-63-1P 329939-64-2P 329939-66-4P  
 329939-68-6P 329939-70-0P 329939-72-2P  
 329939-74-4P 329939-76-6P 329939-77-7P  
 329939-79-9P 329939-81-3P 329939-83-5P  
 329939-85-7P 329939-87-9P 329939-89-1P  
 329939-91-5P 329939-93-7P 329939-95-9P  
 329939-97-1P 329939-99-3P 329940-01-4P  
 329940-03-6P 329940-05-8P 329940-06-9P  
 329940-08-1P 329940-10-5P 329940-13-8P  
 329940-15-0P 329940-17-2P 329940-19-4P  
 329940-21-8P 329940-22-9P 329940-24-1P  
 329940-26-3P 329940-28-5P 329940-30-9P  
 329940-32-1P 329940-35-4P 329940-38-7P  
 329940-40-1P 329940-42-3P 329940-44-5P  
 329940-46-7P 329940-48-9P 329940-50-3P  
 329940-52-5P 329940-54-7P 329940-55-8P  
 329940-57-0P 329940-59-2P 329940-61-6P  
 329940-63-8P 329940-65-0P 329940-67-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of benzophenones and Ph heteroaryl ketones as inhibitors of reverse transcriptase)


RN 329935-96-8 CAPLUS

CN Acetamide, 2-[4-chloro-2-(2-thiazolylcarbonyl)phenoxy]-N-phenyl- (9CI)  
 (CA INDEX NAME)




RN 329935-98-0 CAPLUS

CN Acetamide, 2-[4-chloro-2-(2-thiazolylcarbonyl)phenoxy]-N-1H-indazol-5-yl- (9CI) (CA INDEX NAME)




RN 329936-00-7 CAPLUS

CN Acetamide, 2-[4-chloro-2-(2-thiazolylcarbonyl)phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329936-02-9 CAPLUS

CN Acetamide, 2-[2-(2-benzofuranylcarbonyl)-4-chlorophenoxy]-N-phenyl- (9CI) (CA INDEX NAME)




RN 329936-04-1 CAPLUS

CN Acetamide, 2-[2-(benzo[b]thien-2-ylcarbonyl)-4-chlorophenoxy]-N-phenyl-  
(9CI) (CA INDEX NAME)


RN 329936-06-3 CAPLUS

CN Acetamide, 2-[4-chloro-2-[(1-methyl-1H-pyrrol-2-yl)carbonyl]phenoxy]-N-phenyl- (9CI) (CA INDEX NAME)




RN 329936-08-5 CAPLUS

CN Acetamide, 2-[4-chloro-2-[[5-(2-pyridinyl)-2-thienyl]carbonyl]phenoxy]-N-phenyl- (9CI) (CA INDEX NAME)




RN 329936-11-0 CAPLUS

CN Acetamide, 2-[4-chloro-2-[(5-methyl-3-isoxazolyl)carbonyl]phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329936-13-2 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-fluorobenzoyl)phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329936-15-4 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-fluorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329936-17-6 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-chlorobenzoyl)phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329936-19-8 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-chlorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329936-21-2 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329936-23-4 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 329936-25-6 CAPLUS


CN Acetamide, 2-[4-chloro-2-(3-methylbenzoyl)phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329936-27-8 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]-N-[2-methyl-4-[3-(1-pyrrolidinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 329936-29-0 CAPLUS  
 CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[(1-methyl-1H-imidazol-2-yl)carbonyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 329936-31-4 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(2-thiazolylcarbonyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329936-33-6 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-[3-(1-pyrrolidinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)




PAGE 1-A




RN 329936-35-8 CAPLUS

CN Acetamide, 2-[4-chloro-2-(4-fluorobenzoyl)phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329936-37-0 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329936-39-2 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,4-difluorobenzoyl)phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329936-41-6 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329936-43-8 CAPLUS

CN Acetamide, N-5-benzothiazolyl-2-(2-benzoyl-4-chlorophenoxy)- (9CI) (CA INDEX NAME)




RN 329936-45-0 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-dichlorobenzoyl)phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329936-47-2 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-(1,3-dihydro-1,3-dioxo-5-isobenzofuranyl)- (9CI) (CA INDEX NAME)




RN 329936-49-4 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-fluoro-5-(trifluoromethyl)benzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329936-51-8 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-dichlorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329936-53-0 CAPLUS

CN Acetamide, N-6-benzothiazolyl-2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]-  
(9CI) (CA INDEX NAME)




RN 329936-55-2 CAPLUS

CN Acetamide, N-6-benzothiazolyl-2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-  
(9CI) (CA INDEX NAME)




RN 329936-57-4 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-(2-methyl-5-benzothiazolyl)-  
(9CI) (CA INDEX NAME)




RN 329936-59-6 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-(2-methyl-6-benzothiazolyl)- (9CI) (CA INDEX NAME)




RN 329936-61-0 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]-N-(2-methyl-5-benzothiazolyl)- (9CI) (CA INDEX NAME)




RN 329936-63-2 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329936-65-4 CAPLUS

CN Acetamide, N-1,2-benzisothiazol-5-yl-2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329936-67-6 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-(1H-imidazol-2-ylsulfonyl)-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 329936-69-8 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-(2-thiazolylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329936-71-2 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-(2-thiazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329936-73-4 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-(2-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329936-75-6 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-[(3-hydroxypropyl)sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 329936-77-8 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[(ethylamino)sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 329936-79-0 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(1H-1,2,4-triazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 329936-81-4 CAPLUS


CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329936-83-6 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)phenyl]-2-(2-benzoyl-4-chlorophenoxy)-  
(9CI) (CA INDEX NAME)

RN 329936-85-8 CAPLUS


CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(1,2,3-thiadiazol-4-yl)phenyl]-  
(9CI) (CA INDEX NAME)

RN 329936-87-0 CAPLUS

CN Acetamide, 2-[4-chloro-2-(2-thienylcarbonyl)phenoxy]-N-1H-indazol-5-yl-  
(9CI) (CA INDEX NAME)


RN 329936-89-2 CAPLUS

CN Acetamide, 2-[4-chloro-2-(2-furanylcarbonyl)phenoxy]-N-1H-indazol-5-yl-  
(9CI) (CA INDEX NAME)




RN 329936-91-6 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-thienylcarbonyl)phenoxy]-N-1H-indazol-5-yl-  
(9CI) (CA INDEX NAME)




RN 329936-93-8 CAPLUS

CN Acetamide, 2-[4-chloro-2-(2-thienylcarbonyl)phenoxy]-N-[2-methyl-4-[3-(4-morpholinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329936-95-0 CAPLUS

CN Acetamide, 2-[4-chloro-2-(2-thienylcarbonyl)phenoxy]-N-[4-(1,1-dioxido-4-thiomorpholinyl)-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 329936-97-2 CAPLUS

CN Acetamide, 2-[4-chloro-2-(2-thienylcarbonyl)phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329936-99-4 CAPLUS

CN Acetamide, 2-[4-chloro-2-(2-furanylcarbonyl)phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329937-01-1 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-(2-benzoyl-4-chlorophenoxy)- (9CI) (CA INDEX NAME)




RN 329937-03-3 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(2-thienylcarbonyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329937-05-5 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329937-07-7 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[1,2,4]triazolo[1,5-a]pyridin-6-yl- (9CI) (CA INDEX NAME)




RN 329937-11-3 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-1H-imidazo[4,5-b]pyridin-6-yl- (9CI) (CA INDEX NAME)




RN 329937-15-7 CAPLUS

CN Acetamide, 2-(4-amino-2-benzoylphenoxy)-N-phenyl- (9CI) (CA INDEX NAME)




RN 329937-17-9 CAPLUS

CN Acetamide, 2-[4-chloro-2-(2-pyridinylcarbonyl)phenoxy]-N-phenyl- (9CI) (CA INDEX NAME)



RN 329937-19-1 CAPLUS


CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)




RN 329937-21-5 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[2-methyl-4-[3-(1-pyrrolidinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 329937-23-7 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[2-methyl-4-[3-(4-morpholinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329937-25-9 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[2-methyl-4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 329937-27-1 CAPLUS


CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[2-methyl-4-[3-(1-oxido-4-thiomorpholinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329937-29-3 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-[3-(1H-imidazol-1-yl)propoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 329937-31-7 CAPLUS


CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-[3-(dimethylamino)propoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 329937-33-9 CAPLUS


CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-2-fluoro-N-[2-methyl-4-[3-(1-pyrrolidinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A







RN 329937-35-1 CAPLUS  
 CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-[[3-(dimethylamino)propyl]thio]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 329937-37-3 CAPLUS  
 CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-1H-indazol-5-yl- (9CI) (CA INDEX NAME)




RN 329937-39-5 CAPLUS  
 CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-1H-indol-5-yl- (9CI) (CA INDEX NAME)




RN 329937-40-8 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)- (9CI) (CA INDEX NAME)




RN 329937-42-0 CAPLUS

CN Acetamide, N-1H-benzotriazol-5-yl-2-(2-benzoyl-4-chlorophenoxy)- (9CI) (CA INDEX NAME)




RN 329937-44-2 CAPLUS

CN Benzamide, 4-[[ (2-benzoyl-4-chlorophenoxy) acetyl] amino]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 329937-45-3 CAPLUS

CN Benzamide, 4-[[ (2-benzoyl-4-chlorophenoxy) acetyl] amino]- (9CI) (CA INDEX NAME)




RN 329937-48-6 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-pyridinylcarbonyl)phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329937-50-0 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-pyridinylcarbonyl)phenoxy]-N-1H-indazol-5-yl- (9CI) (CA INDEX NAME)




RN 329937-52-2 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-thienylcarbonyl)phenoxy]-N-[4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329937-54-4 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-thienylcarbonyl)phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329937-56-6 CAPLUS

CN Acetamide, 2-[4-chloro-2-[[1-(phenylmethyl)-1H-imidazol-2-yl]carbonyl]phenoxy]-N-phenyl- (9CI) (CA INDEX NAME)




RN 329937-58-8 CAPLUS

CN Acetamide, 2-[4-chloro-2-[(1-methyl-1H-imidazol-2-yl)carbonyl]phenoxy]-N-phenyl- (9CI) (CA INDEX NAME)




RN 329937-60-2 CAPLUS

CN Acetamide, 2-[4-chloro-2-[(4-cyano-2-thienyl)carbonyl]phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329937-61-3 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[(4-cyano-2-thienyl)carbonyl]phenoxy]- (9CI) (CA INDEX NAME)





RN 329937-63-5 CAPLUS

CN Acetamide, 2-[4-chloro-2-[(5-cyano-2-thienyl)carbonyl]phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329937-65-7 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-[(5-bromo-3-pyridinyl)carbonyl]-4-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 329937-67-9 CAPLUS

CN Acetamide, 2-[2-[(5-bromo-3-pyridinyl)carbonyl]-4-chlorophenoxy]-N-(6-methyl-1H-benzimidazol-5-yl)- (9CI) (CA INDEX NAME)




RN 329937-69-1 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-[(trifluoromethyl)thio]benzoyl]phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329937-71-5 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[3-[(trifluoromethyl)thio]benzoyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 329937-73-7 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[3-[(trifluoromethyl)sulfonyl]benzoyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 329937-75-9 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-ethynylbenzoyl)phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329937-76-0 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-ethynylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329937-78-2 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-ethynylbenzoyl)phenoxy]-N-[2-methyl-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329937-80-6 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[3-(cyclopentylethynyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 329937-83-9 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[3-(phenylethynyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 329937-86-2 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329937-89-5 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]-N-[2-methyl-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329937-91-9 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-(6-methyl-1H-benzimidazol-5-yl)- (9CI) (CA INDEX NAME)




RN 329937-93-1 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-(6-methyl-1H-benzimidazol-5-yl)- (9CI) (CA INDEX NAME)




RN 329937-95-3 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-dichlorobenzoyl)phenoxy]-N-(6-methyl-1H-benzimidazol-5-yl)- (9CI) (CA INDEX NAME)




RN 329937-97-5 CAPLUS

CN Acetamide, 2-[2-[3,5-bis(trifluoromethyl)benzoyl]-4-chlorophenoxy]-N-(6-methyl-1H-benzimidazol-5-yl)- (9CI) (CA INDEX NAME)




RN 329937-98-6 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-5-[3-(1-pyrrolidinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329938-00-3 CAPLUS

CN Acetamide, N-[4-[3-(aminosulfonyl)propoxy]-2-methylphenyl]-2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329938-02-5 CAPLUS

CN Acetamide, N-[4-[3-(aminosulfonyl)propoxy]-2-methylphenyl]-2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 329938-04-7 CAPLUS


CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-[3-[[1,1-dimethylethyl)amino)sulfonyl]propoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 329938-06-9 CAPLUS


CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[3-[(dimethylamino)sulfonyl]propoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)

NAME)



RN 329938-08-1 CAPLUS


CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[3-[(methylamino)sulfonyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329938-10-5 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[3-(1H-imidazol-1-yl)propoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 329938-12-7 CAPLUS


CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[(1E)-4-(1-pyrrolidinyl)-1-butenyl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 329938-14-9 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 329938-16-1 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-(6-chloro-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 329938-20-7 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-(1,3-dihydro-2,2-dioxido-5-benzothien-5-yl)- (9CI) (CA INDEX NAME)




RN 329938-26-3 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 329938-28-5 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329938-30-9 CAPLUS

CN Acetamide, 2-[2-(3-cyanobenzoyl)-4-(trifluoromethyl)phenoxy]-N-(6-methyl-1H-benzimidazol-5-yl)- (9CI) (CA INDEX NAME)




RN 329938-32-1 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-(4-methyl-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 329938-34-3 CAPLUS

CN 4-Morpholinepropanamide, N-[4-[[[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]- (9CI) (CA INDEX NAME)




RN 329938-36-5 CAPLUS  
 CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-[[3-(1H-imidazol-1-yl)propyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 329938-38-7 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-[[3-(diethylamino)propyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 329938-40-1 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-[[3-(1-pyrrolidinyl)propyl]amino]phenyl]- (9CI) (CA INDEX NAME)




PAGE 1-A




RN 329938-42-3 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-[[3-(4-morpholinyl)propyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 329938-45-6 CAPLUS


CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[(cyclopropylamino)sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 329938-47-8 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-(1-pyrrolidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 329938-48-9 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[3-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329938-50-3 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329938-52-5 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(cyanomethyl)phenyl]- (9CI)  
(CA INDEX NAME)




RN 329938-54-7 CAPLUS

CN Benzoic acid, 4-[[2-(2-benzoyl-4-chlorophenoxy)acetyl]amino]-,  
2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 329938-56-9 CAPLUS


CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(hydroxymethyl)phenyl]-  
(9CI) (CA INDEX NAME)



RN 329938-57-0 CAPLUS


CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[2-(4-morpholinyl)phenyl]-

(9CI) (CA INDEX NAME)




RN 329938-58-1 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)phenyl]-2-[2-(4-chlorobenzoyl)-4-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 329938-60-5 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-[(5-methyl-3-isoxazolyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329938-62-7 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329938-63-8 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(methylamino)sulfonyl]phenyl- (9CI) (CA INDEX NAME)




RN 329938-65-0 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(methylsulfonyl)amino]phenyl- (9CI) (CA INDEX NAME)



RN 329938-66-1 CAPLUS


CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 329938-68-3 CAPLUS


CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-[(1R)-1-hydroxyethyl]phenyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 329938-70-7 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329938-72-9 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329938-74-1 CAPLUS

CN Benzoic acid, 4-[[ (2-benzoyl-4-chlorophenoxy)acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 329938-76-3 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[2-methyl-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329938-78-5 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(4-morpholinyl)-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329938-80-9 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(4-thiomorpholinyl)-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329938-82-1 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 329938-84-3 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[2-methyl-4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 329938-88-7 CAPLUS


CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[2-methyl-4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)

piperazinyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 329938-84-3


CMF C26 H26 Cl N3 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 329938-90-1 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(hydroxymethyl)-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 329938-91-2 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 329938-94-5 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(1-hydroxypropyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329938-95-6 CAPLUS

CN Acetamide, 2-[4-chloro-2-(4-pyridinylcarbonyl)phenoxy]-N-phenyl- (9CI) (CA INDEX NAME)




RN 329938-96-7 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2,6-dichlorophenyl]-2-(2-benzoyl-4-chlorophenoxy)- (9CI) (CA INDEX NAME)




RN 329938-98-9 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methoxyphenyl]-2-(2-benzoyl-4-chlorophenoxy)- (9CI) (CA INDEX NAME)




RN 329939-00-6 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-(2-chloro-4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 329939-02-8 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-(2,4-dihydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 329939-04-0 CAPLUS

CN Acetamide, N-[3-(aminosulfonyl)phenyl]-2-(2-benzoyl-4-chlorophenoxy)-  
(9CI) (CA INDEX NAME)




RN 329939-08-4 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-nitrophenyl]-2-(2-benzoyl-4-chlorophenoxy)- (9CI) (CA INDEX NAME)




RN 329939-10-8 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-1H-indazol-6-yl- (9CI) (CA INDEX NAME)



RN 329939-12-0 CAPLUS


CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[2-chloro-4-[3-(dimethylamino)propoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329939-14-2 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-(3-chloro-1H-indazol-5-yl)- (9CI) (CA INDEX NAME)




RN 329939-16-4 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-chlorophenyl]-2-(2-benzoyl-4-chlorophenoxy)- (9CI) (CA INDEX NAME)




RN 329939-18-6 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[2-methyl-4-(4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329939-20-0 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329939-22-2 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[2-cyano-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 329939-24-4 CAPLUS


CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[2-methyl-4-(4-oxo-1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 329939-26-6 CAPLUS


CN Acetamide, 2-[4-chloro-2-(2-furanylcarbonyl)phenoxy]-N-1H-indazol-6-yl-

(9CI) (CA INDEX NAME)




RN 329939-28-8 CAPLUS

CN Acetamide, 2-[4-chloro-2-(2-furanylcarbonyl)phenoxy]-N-(4-methyl-1H-indazol-5-yl)- (9CI) (CA INDEX NAME)




RN 329939-29-9 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-(4-methyl-1H-indazol-5-yl)- (9CI) (CA INDEX NAME)




RN 329939-31-3 CAPLUS

CN Acetamide, 2-[4-chloro-2-(2-thienylcarbonyl)phenoxy]-N-(4-methyl-1H-indazol-5-yl)- (9CI) (CA INDEX NAME)




RN 329939-32-4 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-(5-methyl-1H-indazol-6-yl)-  
(9CI) (CA INDEX NAME)




RN 329939-37-9 CAPLUS

CN Acetamide, 2-[4-chloro-2-(4-cyanobenzoyl)phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329939-39-1 CAPLUS

CN Acetamide, 2-[4-chloro-2-(2-cyanobenzoyl)phenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329939-41-5 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-(7-methyl-1H-indazol-6-yl)-  
(9CI) (CA INDEX NAME)




RN 329939-44-8 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-(3-bromobenzoyl)-4-chlorophenoxy]- (9CI) (CA INDEX NAME)



RN 329939-45-9 CAPLUS

CN Acetamide, 2-[2-(3-bromobenzoyl)-4-chlorophenoxy]-N-[2-methyl-4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329939-48-2 CAPLUS

CN Acetamide, 2-[4-chloro-2-(2-furanylcarbonyl)phenoxy]-N-[2-methyl-4-(1-piperazinyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 329939-47-1


CMF C24 H24 Cl N3 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 329939-50-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[[4-chloro-2-(2-furanylcarbonyl)phenoxy]acetyl]amino]-3-methylphenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 329939-52-8 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]-N-(5-methyl-1H-indazol-6-yl)- (9CI) (CA INDEX NAME)




RN 329939-54-0 CAPLUS

Acetamide, 2-[4-chloro-2-(3,5-dichlorobenzoyl)phenoxy]-N-(5-methyl-1H-indazol-6-yl)- (9CI) (CA INDEX NAME)




RN 329939-55-1 CAPLUS

Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-(5-methyl-1H-indazol-6-yl)- (9CI) (CA INDEX NAME)




RN 329939-57-3 CAPLUS

Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-(5-methyl-1H-indazol-6-yl)- (9CI) (CA INDEX NAME)




RN 329939-58-4 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-(6-methyl-5-benzothiazolyl)- (9CI) (CA INDEX NAME)




RN 329939-59-5 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-(1,1-dioxido-2,3-dihydrobenzo[b]thien-6-yl)- (9CI) (CA INDEX NAME)




RN 329939-61-9 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-dimethoxybenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329939-63-1 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-(3-bromo-5-chlorobenzoyl)-4-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 329939-64-2 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329939-66-4 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-dimethylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329939-68-6 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329939-70-0 CAPLUS

CN Acetamide, N-[6-(aminosulfonyl)-4-methyl-3-pyridinyl]-2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 329939-72-2 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-cyano-5-fluorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329939-74-4 CAPLUS

CN Acetamide, N-[6-(aminosulfonyl)-4-methyl-3-pyridinyl]-2-[4-chloro-2-(3-cyano-5-fluorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329939-76-6 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-cyano-5-ethylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329939-77-7 CAPLUS

CN Acetamide, N-[6-(aminosulfonyl)-2-methyl-3-pyridinyl]-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329939-79-9 CAPLUS

CN Acetamide, N-[5-(aminosulfonyl)-3-methyl-2-pyridinyl]-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329939-81-3 CAPLUS


CN Acetamide, 2-[4-chloro-2-{3-fluoro-5-(trifluoromethyl)benzoyl}phenoxy]-N-(2,3-dihydro-1H-indol-6-yl)- (9CI) (CA INDEX NAME)




RN 329939-83-5 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-[[2-(1-pyrrolidinyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 329939-85-7 CAPLUS



CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-  
[(cyclopropylamino)sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)

RN 329939-87-9 CAPLUS


CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-  
[[cyclopropylmethyl]amino]sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX  
NAME)

RN 329939-89-1 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-(1-  
pyrrolidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329939-91-5 CAPLUS  
 CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-  
 [(diethylamino)sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 329939-93-7 CAPLUS  
 CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-

[(ethylamino)sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 329939-95-9 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-[[[2-(2-pyridinyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329939-97-1 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-[[[3-(4-morpholinyl)propyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329939-99-3 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-[[[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329940-01-4 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-[[methyl[2-(2-pyridinyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329940-03-6 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-[(3-pyridinylmethyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329940-05-8 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-[(4-pyridinylmethyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329940-06-9 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-[(2-hydroxyethyl)amino]sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 329940-08-1 CAPLUS

CN Acetamide, N-[4-[(1H-benzotriazol-5-ylamino)sulfonyl]-2-methylphenyl]-2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329940-10-5 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[(diethylamino)sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 329940-13-8 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-  
[4-[[[(cyclopropylmethyl)amino]sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX  
NAME)



RN 329940-15-0 CAPLUS


CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-  
[4-[[[(3-methoxyphenyl)methyl]amino]sulfonyl]-2-methylphenyl]- (9CI) (CA  
INDEX NAME)



RN 329940-17-2 CAPLUS


CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-  
[4-[[[(2-methoxyethyl)amino]sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX  
NAME)

NAME)




RN 329940-19-4 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[[2-cyanoethyl]cyclopropylamino]sulfonyl]-2-methylphenyl- (9CI) (CA INDEX NAME)




RN 329940-21-8 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[[[2-(2-thienyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329940-22-9 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[(1-phenylpropyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329940-24-1 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[methyl[2-(2-pyridinyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329940-26-3 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329940-28-5 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-(3-bromo-5-methylbenzoyl)-4-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 329940-30-9 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[[[(4-methoxyphenyl)methyl]amino]sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 329940-32-1 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[[[2-(2-pyridinyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329940-35-4 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[[[3-(4-methyl-1-piperazinyl)propyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 329940-38-7 CAPLUS


CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[[[3-(pyridinylmethyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329940-40-1 CAPLUS

CN Acetamide, 2-[2-[3,5-bis(trifluoromethyl)benzoyl]-4-chlorophenoxy]-N-[2-methyl-4-[[[2-(1-pyrrolidinyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 329940-42-3 CAPLUS  
 CN Acetamide, 2-[2-[3,5-bis(trifluoromethyl)benzoyl]-4-chlorophenoxy]-N-[2-methyl-4-[[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]sulfonyl]phenyl]- (9CI)  
 (CA INDEX NAME)




RN 329940-44-5 CAPLUS

CN Acetamide, 2-[2-[3,5-bis(trifluoromethyl)benzoyl]-4-chlorophenoxy]-N-[2-methyl-4-[[[(tetrahydro-2-furanyl)methyl]amino]sulfonyl]phenyl]- (9CI)  
(CA INDEX NAME)




RN 329940-46-7 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[[[(4-pyridinyl)methyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329940-48-9 CAPLUS

CN Acetamide, N-[6-(aminosulfonyl)-4-methyl-3-pyridinyl]-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329940-50-3 CAPLUS


CN Acetamide, N-[6-(aminosulfonyl)-4-methyl-3-pyridinyl]-2-[2-(3-bromo-5-methylbenzoyl)-4-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 329940-52-5 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]-N-[4-[3-(2,5-dihydro-1H-pyrrol-1-yl)propoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 329940-54-7 CAPLUS  
 CN Acetamide, 2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]-N-[4-[3-(2,5-dihydro-1H-pyrrol-1-yl)propoxy]-2-methylphenyl]-, monohydrochloride (9CI)  
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN 329940-55-8 CAPLUS  
 CN Acetamide, 2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]-N-[2-methyl-4-  
 [(4-morpholinylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329940-57-0 CAPLUS

CN Acetamide, N-[6-(aminosulfonyl)-4-methyl-3-pyridinyl]-2-[4-chloro-2-(3,5-dicyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329940-59-2 CAPLUS

CN Acetamide, N-[4-[3-[(aminocarbonyl)amino]propoxy]-2-methylphenyl]-2-[4-chloro-2-(3-fluoro-5-(trifluoromethyl)benzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329940-61-6 CAPLUS

CN Acetamide, N-[4-[3-[(aminocarbonyl)amino]propoxy]-2-methylphenyl]-2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 329940-63-8 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[2-(2-methoxyethoxy)ethoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 329940-65-0 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-cyano-5-fluorobenzoyl)phenoxy]-N-[4-[2-(2-methoxyethoxy)ethoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 329940-67-2 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]-N-[4-[2-(2-methoxyethoxy)ethoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)





IT 329940-69-4P 329940-71-8P 329940-73-0P  
 329940-75-2P 329940-77-4P 329940-79-6P  
 329940-81-0P 329940-83-2P 329940-85-4P  
 329940-87-6P 329940-89-8P 329940-91-2P  
 329940-93-4P 329940-95-6P 329940-97-8P  
 329940-99-0P 329941-14-2P 329941-16-4P  
 329941-18-6P 329941-21-1P 329941-23-3P  
 329941-25-5P 329941-27-7P 329941-29-9P  
 329941-34-6P 329966-53-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of benzophenones and Ph heteroaryl ketones as inhibitors of reverse transcriptase)


RN 329940-69-4 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[(5-cyano-3-pyridinyl)carbonyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 329940-71-8 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[(2-chloro-6-methyl-4-pyridinyl)carbonyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 329940-73-0 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-dibromobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329940-75-2 CAPLUS


CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[(methylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 329940-77-4 CAPLUS



CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-

[4-[(dimethylamino)sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)





RN 329940-79-6 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-[(6-bromo-2-pyridinyl)carbonyl]-4-chlorophenoxy]- (9CI) (CA INDEX NAME)





RN 329940-81-0 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[(6-cyano-2-pyridinyl)carbonyl]phenoxy]- (9CI) (CA INDEX NAME)





RN 329940-83-2 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-[4-bromo-2-(trifluoromethyl)benzoyl]-4-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 329940-85-4 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[4-cyano-2-(trifluoromethyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 329940-87-6 CAPLUS

CN Acetamide, N-[6-(aminosulfonyl)-4-methyl-3-pyridinyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329940-89-8 CAPLUS


CN Acetamide, N-[6-(aminosulfonyl)-2-methyl-3-pyridinyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329940-91-2 CAPLUS


CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-

[2-methyl-4-[3-(1H-1,2,4-triazol-1-yl)propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 329940-93-4 CAPLUS


CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-[3-(1H-1,2,4-triazol-1-yl)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329940-95-6 CAPLUS

CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[3-(2,5-dihydro-1H-pyrrol-1-yl)propoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 329940-97-8 CAPLUS  
 CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[3-(3-thiazolidinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 329940-99-0 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 329941-14-2 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(1H-imidazol-1-yl)phenyl]-  
(9CI) (CA INDEX NAME)




RN 329941-16-4 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-[(2-thiazolylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329941-18-6 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(1-hydroxyethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329941-21-1 CAPLUS

CN Acetamide, 2-[4-chloro-2-(2-thienylcarbonyl)phenoxy]-N-[4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329941-23-3 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-furanylcarbonyl)phenoxy]-N-[4-(1-oxido-4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)





RN 329941-25-5 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-(2-bromobenzoyl)-4-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 329941-27-7 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-pyridinylcarbonyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329941-29-9 CAPLUS


CN Acetamide, N-6-benzothiazolyl-2-(2-benzoyl-4-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 329941-34-6 CAPLUS


CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-[(1S)-1-hydroxyethyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 329966-53-2 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-(3-cyanobenzoyl)-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




IT 329943-82-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of benzophenones and Ph heteroaryl ketones as inhibitors of reverse transcriptase)


RN 329943-82-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[2-benzoyl-4-chlorophenoxy)acetyl]amino]-3-methylphenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2000:550031 CAPLUS  
 DN 134:162784  
 TI Palladium-catalyzed synthesis of carbonyl-labeled benzophenone derivatives from [11C]carbon monoxide  
 AU Nader, M. W.; Zeisler, S. K.; Theobald, A. M.; Oberdorfer, F.  
 CS Department of Radiochemistry, German Cancer Research Center (DKFZ), Heidelberg, D-69120, Germany  
 SO Synthesis and Applications of Isotopically Labelled Compounds 1997, Proceedings of the International Symposium, 6th, Philadelphia, PA, United States, Sept. 14-18, 1997 (1998), Meeting Date 1997, 395-397. Editor(s): Heys, J. Richard; Melillo, David G. Publisher: John Wiley & Sons Ltd., Chichester, UK.  
 CODEN: 69AGFQ  
 DT Conference  
 LA English  
 AB A symposium report on the prepn. of 2-Ph11COC6H4OCH2CONHPh by reaction of PhB(OH)2 with 2-IC6H4OCH2CONHPh and 11CO in the presence of (Ph3P)2PdCl2.  
 IT **324743-12-6P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (palladium-catalyzed synthesis of carbonyl-labeled benzophenone derivs. from [11C]carbon monoxide)  
 RN 324743-12-6 CAPLUS  
 CN Acetamide, 2-[2-(benzoyl-carbonyl-11C)phenoxy]-N-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1997:587674 CAPLUS

DN 127:278069

TI Preparation of N-[(2-aminocarbonyl)phenyl]-N-[(N-methylanilino)carbonylmethyl]-2-[3-(3-methylphenyl)ureido]acetamides as CCK and gastrin receptor antagonists

IN Shimamura, Hiroshi; Kamisaki, Toshiaki; Tanaka, Yuji; Takahashi, Kazuyoshi

PA Morishita Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 16 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 09227494	A2	19970902	JP 1996-61729	19960222
PRAI	JP 1996-61729		19960222		
OS	MARPAT 127:278069				

AB Title compds. I (R1 = H, lower alkyl, PhCH<sub>2</sub>; R2, R3 = H, lower alkyl, Ph; R2R3 may form C4-6 alkylene), useful for treatment of anxiety, hypophagia, ulcer, pancreatitis, and other diseases assocd. with CCK or gastrin receptors, are prepd. 2-Amino-N-[2-(isopropylaminocarbonyl)phenyl]-N-[(N-methylanilino)carbonylmethyl]acetamide was treated with 3-methylphenyl isocyanate in THF at room temp. for 24 h to give 78% N-[2-(isopropylaminocarbonyl)phenyl]-N-[(N-methylanilino)carbonylmethyl]-2-[3-(3-methylphenyl)ureido]acetamide, which inhibited binding of CCK-A, CCK-B, and gastrin to their receptors with IC<sub>50</sub> of 2300, 70, and 7.5 nM, resp.

IT 195967-58-9P 195967-62-5P 195967-63-6P



195967-66-9P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of (phenylureido)acetamides as CCK and gastrin receptor antagonists)

RN 195967-58-9 CAPLUS


CN Glycinamide, N-[[[(3-methylphenyl)amino]carbonyl]glycyl-N-methyl-N-phenyl-N2-[2-(1-piperidinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 195967-62-5 CAPLUS

CN Glycinamide, N-[[[(3-methylphenyl)amino]carbonyl]-D-alanyl-N-methyl-N-phenyl-N2-[2-(1-piperidinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195967-63-6 CAPLUS

CN Glycinamide, N-[[[(3-methylphenyl)amino]carbonyl]-L-alanyl-N-methyl-N-phenyl-N2-[2-(1-piperidinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195967-66-9 CAPLUS

CN Glycinamide, N-[[[(3-methylphenyl)amino]carbonyl]-L-phenylalanyl-N-methyl-N-phenyl-N2-[2-(1-piperidinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 195967-72-7P 195967-73-8P 195967-74-9P


195967-77-2P 195967-78-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of (phenylureido)acetamides as CCK and gastrin receptor antagonists)


RN 195967-72-7 CAPLUS

CN Acetamide, N-methyl-N-phenyl-2-[[2-(1-piperidinylcarbonyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 195967-73-8 CAPLUS


CN 2H-Isoindole-2-acetamide, 1,3-dihydro-.alpha.-methyl-N-[2-(methylphenylamino)-2-oxoethyl]-1,3-dioxo-N-[2-(1-piperidinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 195967-74-9 CAPLUS

CN Glycinamide, L-alanyl-N-methyl-N-phenyl-N2-[2-(1-piperidinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195967-77-2 CAPLUS

CN 2H-Isoindole-2-acetamide, 1,3-dihydro-N-[2-(methylphenylamino)-2-oxoethyl]-1,3-dioxo-.alpha.-(phenylmethyl)-N-[2-(1-piperidinylcarbonyl)phenyl]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 195967-78-3 CAPLUS

CN Glycinamide, D-phenylalanyl-N-methyl-N-phenyl-N2-[2-(1-piperidinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1995:538886 CAPLUS  
 DN 122:281444  
 TI Benzophenone Derivatives: A Novel Series of Potent and Selective  
 Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase  
 AU Wyatt, Paul G.; Bethell, Richard C.; Cammack, Nicholas; Charon, Daniel;  
 Dodic, Nerina; Dumaitre, Bernard; Evans, Derek N.; Green, Darren V. S.;  
 Hopewell, Philippa L.; et al.  
 CS Medicinal Chemistry Virology Chemotherapy and Biomolecular Structure  
 Departments, Glaxo Research and Development Limited, Greenford/ Middlesex,  
 UB6 OHE, UK  
 SO Journal of Medicinal Chemistry (1995), 38(10), 1657-65  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 AB A series of benzophenone derivs. has been synthesized and evaluated as  
 inhibitors of HIV-1 reverse transcriptase (RT) and the growth of HIV-1 in  
 MT-4 cells. Through the use of the structure-activity relationships  
 within this series of compds. and computational chem. techniques, a  
 binding conformation is proposed. The SAR also indicated that the major  
 interactions of I with the RT enzyme are through hydrogen bonding of the  
 amide and benzophenone carbonyls and .pi.-orbital interactions with the  
 benzophenone nucleus and an arom. function sepd. from the benzophenone by  
 a suitable spacer group. The crystal structure of compd. I has been detd.  
 A no. of compds. with potent inhibitory activity against HIV-1 RT and HIV  
 in cellular assays at levels comparable with AZT and our efforts to  
 identify a metabolically stable analog are described.  
 IT **163130-71-0P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL  
 (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
 (benzophenone derivs. as selective inhibitors of human immunodeficiency  
 virus type 1 reverse transcriptase)  
 RN 163130-71-0 CAPLUS  
 CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-phenyl- (9CI) (CA INDEX NAME)





IT **163130-64-1P 163130-66-3P 163130-67-4P**  
**163130-68-5P 163130-69-6P 163130-70-9P**  
**163130-72-1P 163130-73-2P 163130-74-3P**  
**163130-75-4P 163130-76-5P 163130-77-6P**  
**163130-78-7P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); BIOL (Biological  
 study); PREP (Preparation)  
 (benzophenone derivs. as selective inhibitors of human immunodeficiency  
 virus type 1 reverse transcriptase)

RN 163130-64-1 CAPLUS  
 CN Acetamide, N-[4-[2-(diethylamino)ethoxy]phenyl]-2-[2-(4-methoxybenzoyl)phenoxy]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 163130-63-0  
 CMF C28 H32 N2 O5



CM 2



CRN 144-62-7  
 CMF C2 H2 O4



RN 163130-66-3 CAPLUS  
 CN Acetamide, N-[4-[2-(diethylamino)ethoxy]phenyl]-2-[2-(4-fluorobenzoyl)phenoxy]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 163130-65-2  
 CMF C27 H29 F N2 O4




CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.




RN 163130-67-4 CAPLUS  
CN Acetamide, 2-(2-benzoylphenoxy)-N-[4-[2-(diethylamino)ethoxy]phenyl]-(9CI) (CA INDEX NAME)




RN 163130-68-5 CAPLUS  
CN Acetamide, 2-(2-benzoyl-5-methoxyphenoxy)-N-[4-[2-(diethylamino)ethoxy]phenyl]-(9CI) (CA INDEX NAME)



RN 163130-69-6 CAPLUS  
CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-[2-(diethylamino)ethoxy]phenyl]-(9CI) (CA INDEX NAME)




RN 163130-70-9 CAPLUS  
CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-[3-(dimethylamino)propoxy]phenyl]-(9CI) (CA INDEX NAME)




RN 163130-72-1 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-fluorophenoxy)-N-phenyl- (9CI) (CA INDEX NAME)




RN 163130-73-2 CAPLUS

CN Acetamide, 2-[2-benzoyl-4-(1H-imidazol-1-yl)phenoxy]-N-phenyl- (9CI) (CA INDEX NAME)




RN 163130-74-3 CAPLUS

CN Acetamide, 2-(2-benzoyl-4,6-dichlorophenoxy)-N-phenyl- (9CI) (CA INDEX NAME)




RN 163130-75-4 CAPLUS

CN Acetamide, 2-(2-benzoyl-4,5-dichlorophenoxy)-N-phenyl- (9CI) (CA INDEX NAME)




RN 163130-76-5 CAPLUS

CN Acetamide, 2-(2-benzoyl-3,4-dichlorophenoxy)-N-phenyl- (9CI) (CA INDEX NAME)




RN 163130-77-6 CAPLUS

CN Acetamide, 2-[4-chloro-2-(3-pyridinylcarbonyl)phenoxy]-N-phenyl- (9CI) (CA INDEX NAME)



RN 163130-78-7 CAPLUS

CN Acetamide, 2-[4-chloro-2-(cyclopentylcarbonyl)phenoxy]-N-phenyl- (9CI) (CA INDEX NAME)



IT 163130-92-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(benzophenone derivs. as selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase)


RN 163130-92-5 CAPLUS

CN Acetamide, 2-(2-benzoylphenoxy)-N-[4-[2-(diethylamino)ethoxy]phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 163130-67-4

CMF C27 H30 N2 O4




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



L4 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1995:777639 CAPLUS  
 DN 123:198616  
 TI Preparation of N-sulfonylindoline derivatives with affinity for  
 vasopressin and oxytocin receptors  
 IN Wagnon, Jean; de Cointet, Paul; Nisato, Dino; Plouzane, Claude;  
 Sereadeil-Legal, Claudine; Tonnerre, Bernard  
 PA Elf Sanofi SA, Fr.  
 SO U.S., 50 pp. Cont.-in-part of U.S. Ser. No.737,655, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5338755	A	19940816	US 1992-923839	19920803
	FR 2665441	A1	19920207	FR 1990-9778	19900731
	FR 2665441	B1	19921204		
	IL 114934	A1	19960804	IL 1991-114934	19910730
	HU 219351	B	20010328	HU 1971-99045	19910731
	FR 2679903	A1	19930205	FR 1991-9908	19910802
	FR 2679903	B1	19931203		
	AU 9224758	A1	19930302	AU 1992-24758	19920731
	AU 658664	B2	19950427		
	BR 9205336	A	19931116	BR 1992-5336	19920731
	JP 06501960	T2	19940303	JP 1993-503337	19920731
	RU 2104268	C1	19980210	RU 1993-5168	19920731
	IL 117592	A1	19990411	IL 1992-117592	19920731
	CZ 288173	B6	20010516	CZ 1993-682	19920731
	CA 2206776	C	20020226	CA 1992-2206776	19920731
	SK 283463	B6	20030805	SK 1993-426	19920731
	NO 9301262	A	19930526	NO 1993-1262	19930401
	NO 180047	B	19961028		
	NO 180047	C	19970205		
	US 5397801	A	19950314	US 1994-240360	19940510
	US 5481005	A	19960102	US 1994-348150	19941128
	US 5578633	A	19961126	US 1995-458614	19950602
	FI 9800175	A	19980127	FI 1998-175	19980127
PRAI	FR 1990-9778	A	19900731		
	US 1991-737655	B2	19910730		
	FR 1991-9908	A	19910802		
	IL 1991-99012	A3	19910730		
	HU 1991-2552	A	19910731		
	CA 1992-2093221	A3	19920731		
	CS 1993-682	A	19920731		
	IL 1992-102703	A3	19920731		
	WO 1992-FR758	A	19920731		
	US 1992-923839	A3	19920803		
	FI 1993-1476	A	19930401		
	US 1993-923839	A3	19930803		
	US 1994-240360	A3	19940510		
	US 1994-348150	A3	19941128		

OS MARPAT 123:198616

AB Title compds. I (R'1 = halo, C1-4 alkyl, HO, C1-4 alkoxy, PhCH<sub>2</sub>O, NC, F3C,  
 O<sub>2</sub>N, H<sub>2</sub>N; R'2 = C1-6 alkyl, C3-7 cycloalkyl, C5-7  
 cycloalkylene, (substituted) Ph, etc.; R'3 = H; R'4 = H<sub>2</sub>NCO, R'6R'7NCO  
 wherein R'6R'7N = satd. 5-membered substituted N-heterocyclyl; R'5 = C1-4  
 alkyl, 1-, 2-naphthyl, (substituted) Ph, etc.; n = m = 0-2) or a salt

thereof, are prepd.  $\text{CH}_2\text{BrCONMe}_2$  (prepn. given) and 5-chloro-2-(tosylamino)phenyl cyclohexyl ketone were reacted to give 2-[N-tosyl-N-(dimethylcarbamoylmethyl)amino]-5-(chlorophenyl) cyclohexyl ketone which in THF was treated with Li diisopropylamide to give after workup trans-I ( $\text{R}'_1 = 5\text{-Cl}$ ,  $\text{R}'_2 = \text{cyclohexyl}$ ,  $\text{R}'_3 = \text{H}$ ,  $\text{R}'_4 = \text{Me}_2\text{NCO}$ ,  $\text{R}'_5 = 4\text{-MeC}_6\text{H}_4$ ,  $m = 0$ ). The  $\text{IC}_{50}$  of I affinity for oxytocin receptors was 10-5-10-8M.


IT 149152-23-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of N-sulfonylindoline derivs. with affinity for vasopressin and oxytocin receptors)

RN 149152-23-8 CAPLUS

CN Acetamide, 2-[[4-chloro-2-(2-chlorobenzoyl)phenyl][(3,4-dimethoxyphenyl)sulfonyl]amino]-N-methyl-N-(1-methyl-4-piperidiny)- (9CI)  
(CA INDEX NAME)



When R' is aryl  
 4 is not het  
 in claims 6.  
 Claims  
 10/12 have R' as het.

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1993:539091 CAPLUS  
 DN 119:139091  
 TI Preparation of 1-phenylsulfonyl-3-hydroxyindoline-2-carboxamides as  
 oxytocin and vasopressin antagonists  
 IN Wagnon, Jean; Serradeil-Legal, Claudine; Tonnerre, Bernard; Plouzane,  
 Claude; Nisato, Dino  
 PA Elf Sanofi SA, Fr.  
 SO Eur. Pat. Appl., 71 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA French  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 526348	A1	19930203	EP 1992-402213	19920803
	EP 526348	B1	19980218		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	FR 2679903	A1	19930205	FR 1991-9908	19910802
	FR 2679903	B1	19931203		
	CA 2093221	AA	19930203	CA 1992-2093221	19920731
	CA 2093221	C	19980922		
	WO 9303013	A1	19930218	WO 1992-FR758	19920731
	W: AU, BR, CA, CS, FI, HU, JP, KR, NO, RU				
	AU 9224758	A1	19930302	AU 1992-24758	19920731
	AU 658664	B2	19950427		
	ZA 9205781	A	19930302	ZA 1992-5781	19920731
	BR 9205336	A	19931116	BR 1992-5336	19920731
	JP 06501960	T2	19940303	JP 1993-503337	19920731
	LT 3064	B	19941025	LT 1992-114	19920731
	LV 10091	B	19950420	LV 1992-87	19920731
	HU 68927	A2	19950828	HU 1993-951	19920731
	IL 102703	A1	19970318	IL 1992-102703	19920731
	JP 2633085	B2	19970723	JP 1992-503337	19920731
	RU 2104268	C1	19980210	RU 1993-5168	19920731
	IL 117592	A1	19990411	IL 1992-117592	19920731
	CZ 288173	B6	20010516	CZ 1993-682	19920731
	CA 2206776	C	20020226	CA 1992-2206776	19920731
	SK 283463	B6	20030805	SK 1993-426	19920731
	AT 163289	E	19980315	AT 1992-402213	19920803
	ES 2117038	T3	19980801	ES 1992-402213	19920803
	NO 9301262	A	19930526	NO 1993-1262	19930401
	NO 180047	B	19961028		
	NO 180047	C	19970205		
	US 5481005	A	19960102	US 1994-348150	19941128
	AU 9511541	A1	19950504	AU 1995-11541	19950203
	AU 691223	B2	19980514		
	FI 9800175	A	19980127	FI 1998-175	19980127
PRAI	FR 1991-9908	A	19910802		
	FR 1990-9778	A	19900731		
	US 1991-737655	B2	19910730		
	CA 1992-2093221	A3	19920731		
	CS 1993-682	A	19920731		
	IL 1992-102703	A3	19920731		
	WO 1992-FR758	A	19920731		
	FI 1993-1476	A	19930401		
	US 1993-923839	A3	19930803		
	US 1994-240360	A3	19940510		

OS MARPAT 119:139091

AB Title compds. [I; R1 = OH, halo, alkyl, alkoxy, etc.; R2 = (cyclo)alkyl, (nitro)phenyl, etc.; R5 = alkyl, (nitro)phenyl, naphthyl, etc.; R6 = alkyl; R6, R7 = 4-piperidiny, 3-azetidiny, etc.; NR6R7 = (thio)morpholino, thiazolidino, piperazino, etc.; m, n = 0-2] were prepd. Thus, 2-amino-5-bromo-2'-fluorobenzophenone was amidated by 3,4-(MeO)2C6H3SO2Cl and the product N-alkylated by BrCH2CONMeCH2CO2Me to give, after cyclization of the product, title compd. II. I had IC50 of 10-9, and 10-5 to 10-8 M, against vasopressin and oxytocin binding, resp., in vitro.


IT 149152-23-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction of, in prepn. of oxytocin and vasopressin antagonists)

RN 149152-23-8 CAPLUS

CN Acetamide, 2-[[4-chloro-2-(2-chlorobenzoyl)phenyl][(3,4-dimethoxyphenyl)sulfonyl]amino]-N-methyl-N-(1-methyl-4-piperidiny)- (9CI)  
(CA INDEX NAME)



L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1992:140018 CAPLUS  
 DN 116:140018  
 TI Silver halide color photographic material  
 IN Yokoyama, Shigeki; Tsukahara, Jiro; Yamazaki, Shigeru  
 PA Fuji Photo Film Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 28 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03198050	A2	19910829	JP 1989-341464	19891227
PRAI	JP 1989-341464		19891227		

AB In the title material comprising a support coated with at least one Ag halide emulsion layer, the said layer or another layer contains a cyan coupler represented by I (R1 = alkyl, alkenyl, cycloalkyl, aryl; R2 = a substituent on benzene ring; R3, R4 = H, alkyl, alkenyl, cycloalkyl, aryl; R5 = aryl; L = O, S; Z = H, a group to be released upon coupling reaction; l = 0 to 4). The title material gives stable color images.

IT **139536-78-0 139536-81-5 139536-82-6**  
 RL: TEM (Technical or engineered material use); USES (Uses)  
 (photog. cyan coupler)


RN 139536-78-0 CAPLUS

CN Tetradecanamide, 2-(2-benzoyl-5-methoxyphenoxy)-N-[4-[[[(4-cyanophenyl)amino]carbonyl]amino]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 139536-81-5 CAPLUS

CN Acetic acid, [2-[[2-(2-benzoylphenoxy)-1-oxododecyl]amino]-5-[[[(4-chloro-3-cyanophenyl)amino]carbonyl]amino]-4-hydroxyphenoxy]-, 1-methylpropyl ester (9CI) (CA INDEX NAME)





RN 139536-82-6 CAPLUS

CN Tetradecanamide, N-[4-[[[(4-cyanophenyl)amino]carbonyl]amino]-3-hydroxyphenyl]-2-[2-(4-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1985:437458 CAPLUS  
 DN 103:37458  
 TI 1-Azacycloalkyl-1,4-benzodiazepin-2-ones with antianxiety-antidepressant actions  
 AU Sugasawa, Tsutomu; Adachi, Makoto; Sasakura, Kazuyuki; Matsushita, Akira; Eigyo, Masami; Shiomi, Teruo; Shintaku, Haruyuki; Takahara, Yukio; Murata, Shunji  
 CS Shionogi Res. Lab., Shionogi and Co., Ltd., Osaka, 553, Japan  
 SO Journal of Medicinal Chemistry (1985), 28(6), 699-707  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DT Journal  
 LA English  
 OS CASREACT 103:37458  
 AB A series of 1-azacycloalkyl-1,4-benzodiazepin-2-ones I and II (R = H, Me, PhCH<sub>2</sub>CH<sub>2</sub>; R<sub>1</sub>, R<sub>2</sub> = H, halo; n = 1, 2) were synthesized from 1-azacycloalkyl-2-benzoylanilines and corresponding imines and then evaluated for their central nervous system activities. Pharmacol. data showed that some of these compds. have potent antidepressant properties, as assessed by their antagonism of tetrabenzine induced ptosis and their inhibition of [3H]norepinephrine uptake into rat brain synaptosomes, as well as their moderate antianxiety properties of preventing of pentylenetetrazol convulsion, suppressing conflict behavior, and displacing potential for [3H]diazepam binding. Secondary function of the azacyclic ring at position 1 was essential for the prodn. of the antidepressant properties. Of these new series, I (R = H; R<sub>1</sub> = R<sub>2</sub> = F) has the potential to become a useful antidepressant drug with a moderate antianxiety property.  
 IT **96129-02-1P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 96129-02-1 CAPLUS  
 CN Acetamide, 2-[[2-chloro-6-(2-fluorobenzoyl)phenyl]amino]-N-(1-methyl-4-piperidiny)- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1983:531288 CAPLUS  
 DN 99:131288  
 TI Photographic elements containing aryloxy substituted photographic couplers  
 IN Lau, Philip Thiam Shin  
 PA Eastman Kodak Co., USA  
 SO Eur. Pat. Appl., 32 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 80355	A1	19830601	EP 1982-306197	19821122
	EP 80355	B1	19850508		
	EP 80355	B2	19940406		
	R: CH, DE, FR, GB, LI				
	US 4401752	A	19830830	US 1981-324237	19811123
	CA 1190930	A1	19850723	CA 1982-411819	19820921
	JP 58095346	A2	19830606	JP 1982-203822	19821122
	JP 05049975	B4	19930727		
	US 103402	H	19830906	US 1983-463425	19830203
PRAI	US 1981-324237		19811123		

AB Photog. two-equiv. dye-forming coupler having good reactivity and capable of yielding high amts. of a dye upon reaction with oxidized color developing agents contains an aryloxy coupling off group having in ortho position a polarizable carbonyl, sulfonyl or phosphinyl moiety-contg. group, and is free of photog. dye and reagent groups. Thus, a poly(ethylene terephthalate) support was coated with a Ag(Br,I) emulsion (0.75 g Ag/m<sup>2</sup>, gelatin 3.78 g/m<sup>2</sup>) contg. I dispersed in 1/2 its wt. of di-Bu phthalate and coated at 2.7 .times. 10<sup>-3</sup> mol/m<sup>2</sup>, overcoated with a gelatin layer contg. a hardener, imagewise exposed, and processed to give an image having a Dmax 2.65 and .gamma. 0.89.

IT **86841-22-7**

RL: USES (Uses)


(photog. element contg.)

RN 86841-22-7 CAPLUS

CN Pentanamide, N-[5-[[4-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxobutyl]amino]-2-chlorophenyl]-4,4-dimethyl-2-[2-(4-morpholinylcarbonyl)phenoxy]-3-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1972:158266 CAPLUS  
 DN 76:158266  
 TI Penicillin reactions. 1. Behavior towards penicillinase  
 AU Brandl, E.  
 CS Forsch. Entwickl., Biochem. Kundl G.m.b.H., Austria  
 SO Scientia Pharmaceutica (1971), 39(4), 267-92  
 CODEN: SCPHA4; ISSN: 0036-8709  
 DT Journal  
 LA German  
 AB Penicillins (128) were compared as to their resistance to a com. *Bacillus cereus* penicillinase and to one isolated from a staphylococcus, their biol. activities, and their chromatog. behavior. In general, it appears that large substituents increase the stability to penicillinase, but also reduce the activity. Resistance to *B. cereus* penicillinase is commoner than that to the staphylococcus type. Those stable to the latter were stable to the former.  
 IT **36225-64-6**  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, with penicillinases)  
 RN 36225-64-6 CAPLUS  
 CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(2-benzoyl-4-chlorophenoxy)acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1962:476386 CAPLUS  
 DN 57:76386  
 OREF 57:15247i,15248a  
 TI Constitution and antibacterial action of semisynthetic  
 phenoxyalkylpenicillins and related compounds  
 AU Bauer, K.; Dillenburg, R.; Koenig, H. B.; Knott, Th.; Meiser, W.; Offe, H.  
 A.; Schmid, J.; Schwartz, J.; Timmler, H.  
 CS Bayer A.-G., Wuppertal-Elberfeld, Germany  
 SO Arzneimittel-Forschung (1962), 12, 736-40  
 CODEN: ARZNAD; ISSN: 0004-4172  
 DT Journal  
 LA Unavailable  
 AB A review of relation of chem. constitution and antibacterial action of 107  
 penicillin derivs., with 13 references.  
 IT **98542-38-2**, 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,  
 6-[2-(2-benzoyl-4-chlorophenoxy)butyramido]-3,3-dimethyl-7-oxo-  
 (bactericidal action of)  
 RN 98542-38-2 CAPLUS  
 CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-(2-benzoyl-4-  
 chlorophenoxy)butyramido]-3,3-dimethyl-7-oxo- (7CI) (CA INDEX NAME)

Absolute stereochemistry.



*Same as  
#12*

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1962:476385 CAPLUS

DN 57:76385

OREF 57:15247h-i

TI Amino acid composition of gramicidin

AU Okuda, Kiyoshi; Lin, Chin-Shin; Winnick, Theodore

CS Univ. of Hawaii, Honolulu

SO Nature (London, United Kingdom) (1962), 195(No. 4846), 1067-9

CODEN: NATUAS; ISSN: 0028-0836

DT Journal

LA Unavailable


AB Purified *Bacillus brevis* gramicidin contg. components A, B, and C was hydrolyzed in acid and chromatographed. Glycine, alanine, and valine occurred in a 1:2:4 ratio. Leucyl + isoleucyl residues totaled 4 relative to glycine; and tryptophan, phenylalanine, and tyrosine totaled 4. Since the chief component, gramicidin A, mol. wt. 3800 by crystallography, contains no tyrosine or phenylalanine, its compn. was detd. as 2 glycine, 4 alanine, 8 valine, 8 leucine, and 8 tryptophan residues, plus 2 ethanolamines. Based on the postulate that B contains 3 phenylalanines and C3 tyrosines, the calcd. percentages of A, B, and C in mixed gramicidin were 79, 5, and 16.

IT **98542-38-2**, 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-(2-benzoyl-4-chlorophenoxy)butyramido]-3,3-dimethyl-7-oxo- (bactericidal action of)

RN 98542-38-2 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-(2-benzoyl-4-chlorophenoxy)butyramido]-3,3-dimethyl-7-oxo- (7CI) (CA INDEX NAME)

Absolute stereochemistry.



*Same as #12*

L4 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1961:27843 CAPLUS

DN 55:27843

OREF 55:5470f-i,5471a-h

TI Derivatives of 6-aminopenicillanic acid. I. Partially synthetic penicillins prepared from .alpha.-aryloxyalkanoic acids

AU Perron, Y. G.; Minor, W. F.; Holdrege, C. T.; Gottstein, W. J.; Godfrey, J. C.; Crast, L. B.; Babel, R. B.; Cheney, L. C.

CS Bristol Labs., Syracuse, NY

SO Journal of the American Chemical Society (1960), 82, 3934-8

CODEN: JACSAT; ISSN: 0002-7863

DT Journal

LA Unavailable

AB A series of new diastereoisomeric I was prepd. by N-acylation of 6-aminopenicillanic acid (II) with racemic .alpha.-aryloxyalkanoic acids, R(ArO)CHCO<sub>2</sub>H (III), and isolated as the K salts. The 2 possible isomers of .alpha.-phenoxyethylpenicillin were prepd. in pure form. p-HOC<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>Ph (140 g.) and 76 g. MeCHClCO<sub>2</sub>H in 400 cc. EtOH treated rapidly with stirring and cooling with 80 g. NaOH in 150 cc. H<sub>2</sub>O, the mixt. refluxed 20 hrs., and worked up gave 140 g. p-PhCH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>CHMeCO<sub>2</sub>H, m. 134-5.degree. (C<sub>6</sub>H<sub>6</sub>-petr. ether); method A. NaOH (20 g.) in 125 cc. H<sub>2</sub>O added below 30.degree. to 76.5 g. MeCHBrCO<sub>2</sub>H, the mixt. treated with 81 g. m-CF<sub>3</sub>C<sub>6</sub>H<sub>4</sub>OH in 100 cc. 5N NaOH, heated 20 hrs. on the steam bath, cooled, acidified to pH 2 with concd. HCl, and the product isolated with Et<sub>2</sub>O yielded 182.5 g. m-CF<sub>3</sub>C<sub>6</sub>H<sub>4</sub>OCHMeCO<sub>2</sub>H, b<sub>8</sub> 140-4.degree., m. 63-6.degree.; method B. PhOH (44.2 g.), 24 g. NaOH, and 600 cc. PhMe refluxed with azeotropic removal of 8.5 cc. H<sub>2</sub>O, treated with 98 g. PrCHBrCO<sub>2</sub>Et, the mixt. refluxed 16 hrs., cooled to 60.degree., refluxed 2 hrs. with 100 cc. MeOH and 29 g. NaOH in 120 cc. H<sub>2</sub>O, dild. with 500 cc. H<sub>2</sub>O, and acidified to pH 2 with 6N H<sub>2</sub>SO<sub>4</sub> gave 88 g. PrCH(OPh)CO<sub>2</sub>H, m. 114-16.degree. (C<sub>6</sub>H<sub>6</sub>-ligroine, b. 60-71.degree.); method C. PhOH (28.2 g.) and 67 g. BuCHBrCO<sub>2</sub>Et added successively to 69 g. Na in 120 cc. abs. EtOH, the mixt. refluxed 18 hrs., treated with 120 cc. 2N NaOH, refluxed 1 hr., and worked up gave 24.6 g. BuCH(OPh)CO<sub>2</sub>H, m. 74-5.5.degree. (ligroine). Similarly were prepd. the following III (R = Me) (Ar, method, % yield, and m.p. given): Ph (IV), A, 86, 116-17.degree.; o-ClC<sub>6</sub>H<sub>4</sub>, A, 28, 114.5-116.degree.; p-ClC<sub>6</sub>H<sub>4</sub>, A, 54, 115-16.degree.; p-MeOC<sub>6</sub>H<sub>4</sub>, B, 63, 92-3.degree.; p-cyclohexylphenyl, A, 63, 125-6.degree.; p-AcNHC<sub>6</sub>H<sub>4</sub> (V), B, 67, 176-7.degree.; p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, B, 21, 140-1.degree.; 3,4-CF<sub>3</sub>(O<sub>2</sub>N)C<sub>6</sub>H<sub>3</sub>, A, 60, 90-1.degree.; 3,5-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, B, 41, 118-19.degree.; 2,4-ClPhC<sub>6</sub>H<sub>3</sub>, C, 61, 145-6.degree.; 4,2-Cl(PhCH<sub>2</sub>)C<sub>6</sub>H<sub>3</sub>, C, 46, 115-16.degree.; 2,4-Bz(MeO)C<sub>6</sub>H<sub>3</sub>, C, 31, 130-1.degree.; 4,3,5-ClMe<sub>2</sub>C<sub>6</sub>H<sub>2</sub>, B, 37, 136-8.degree.; C<sub>6</sub>Cl<sub>5</sub>, C, 60, 173-4.degree.; and EtCH(OPh)CO<sub>2</sub>H, A, 69, 82-3.degree.. IV resolved with yohimbine-HCl gave d-IV, m. 86.5-88.degree., [.alpha.]<sub>D</sub><sup>25</sup> 39.8.degree. (c 1, abs. EtOH); the mother liquor evapd., the residue treated with dil. H<sub>2</sub>SO<sub>4</sub>, extd. with Et<sub>2</sub>O, the residual crude l-IV (27 g.) slurried with CHCl<sub>3</sub> at room temp., filtered to remove 10 g. dl-IV, the residue from the filtrate slurried with 150 cc. boiling cyclohexane, filtered, and the filtrate evapd. gave 14.7 g. l-IV, m. 86-7.5.degree., [.alpha.]<sub>D</sub><sup>25</sup> -39.5.degree. (c 1, abs. EtOH). IV (166 g.), 800 cc. C<sub>6</sub>H<sub>6</sub>, and 2 cc. C<sub>5</sub>H<sub>5</sub>N treated dropwise with stirring during 0.5 hr. with 107.4 cc. SOCl<sub>2</sub> at reflux, the mixt. refluxed 1 hr., and worked up gave 146 g. MeCH(OPh)COCl (VI), b<sub>18</sub> 114-15.degree.. II (54 g.) and 105 g. NaHCO<sub>3</sub> in 1.2 l. H<sub>2</sub>O treated in 1 min. with 60 g. VI in 100 cc. Me<sub>2</sub>CO, the mixt. stirred 20 min. at 10-15.degree., washed with iso-BuAc, layered with 500 cc. iso-BuAc, acidified to pH 5 at 5-10.degree. with 5M H<sub>2</sub>SO<sub>4</sub>, and the org. layer worked up gave 76 g. I (Ar = Ph, R = Me) (VII), decompd. at 230-2.degree.; method A. V (31.8 g.), 21.2 cc. Et<sub>3</sub>N, 330 cc. dioxane, and


65 cc. Me<sub>2</sub>CO treated dropwise with stirring at 0.degree. with 19.7 g. ClCO<sub>2</sub>CH<sub>2</sub>CHMe<sub>2</sub>, the mixt. stirred 45 min. at 0.degree., treated with 21.6 g. II, 14.1 cc. Et<sub>3</sub>N, and 30 cc. H<sub>2</sub>O, stirred 1 hr. at 5-8.degree., treated with 10.9 g. NaHCO<sub>3</sub> in 700 cc. iced H<sub>2</sub>O, washed with Et<sub>2</sub>O, acidified with 63 cc. 6N H<sub>2</sub>SO<sub>4</sub>, extd. with iso-BuAc, the washed ext. treated with 40 cc. 50% BuEtCHCO<sub>2</sub>K in BuOH, and the soln. dild. with Me<sub>2</sub>CO and Et<sub>2</sub>O gave 47.1 g. I (Ar = p-AcNHC<sub>6</sub>H<sub>4</sub>, R = Me), decompd. at 223-6.degree. (aq. Me<sub>2</sub>CO); method B. Similarly were prepd. the following I (R = Me) (Ar, method, % yield, and decompn. temp. given): o-ClC<sub>6</sub>H<sub>4</sub>, A, 50, 229-30.degree.; p-ClC<sub>6</sub>H<sub>4</sub>, A, 61, 224-5.degree.; 2,4-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>.cntdot.H<sub>2</sub>O, B, 61, 203-5.degree.; 2,5-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, B, 45, 200-4.degree.; 2,4-Br<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, B, 42, 217-18.degree.; 2,4,6-Cl<sub>3</sub>C<sub>6</sub>H<sub>2</sub>, B, 10, 163-5.degree.; C<sub>6</sub>Cl<sub>5</sub>, B, 35, 189-92.degree.; m-CF<sub>3</sub>C<sub>6</sub>H<sub>4</sub>, B, 26, 188-90.degree.; p-MeOC<sub>6</sub>H<sub>4</sub>, B, 34, 211-14.degree.; p-PhCH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>-H<sub>2</sub>O, A, 79, 228-9.degree.; p-Me<sub>3</sub>CC<sub>6</sub>H<sub>4</sub>, B, 46, 219-20.degree.; p-EtMe<sub>2</sub>CC<sub>6</sub>H<sub>4</sub>, B, 33, above 125.degree.; p-cyclohexylphenyl-H<sub>2</sub>O, A, 79, 230-1.degree.; p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, B, 71, 202-3.degree.; 3,4-CF<sub>3</sub>(O<sub>2</sub>N)C<sub>6</sub>H<sub>3</sub>, B, 40, 203-5.degree.; 3,5-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, B, 60, 220-2.degree.; 2,4-ClPhC<sub>6</sub>H<sub>3</sub>.cntdot.H<sub>2</sub>O, B, 21, above 175.degree.; 4,2-Cl(PhCH<sub>2</sub>)C<sub>6</sub>H<sub>3</sub>.cntdot.H<sub>2</sub>O, A, 42, 230-1.degree.; 4,3,5-ClMe<sub>2</sub>C<sub>6</sub>H<sub>2</sub>, B, 31, 210-13.degree.; 2,4-Bz(MeO)C<sub>6</sub>H<sub>3</sub>.cntdot.H<sub>2</sub>O, A, 63, above 105.degree.. d-IV (16.6 g.) in 100 cc. tetrahydrofuran treated with cooling and stirring with 10.1 g. Et<sub>3</sub>N, the mixt. cooled to -15.degree., treated with 13.6 g. ClCO<sub>2</sub>CH<sub>2</sub>CHMe<sub>2</sub> and then with 21.6 g. II in 35 cc. H<sub>2</sub>O and 15 cc. Et<sub>3</sub>N, the mixt. stirred 25 min. at 25-7.degree., dild. with 250 cc. H<sub>2</sub>O, washed with Et<sub>2</sub>O, layered with Et<sub>2</sub>O, acidified to pH 2 with 3N H<sub>2</sub>SO<sub>4</sub>, and the Et<sub>2</sub>O layer worked up gave 31.7 g. d-VII, decompd. at 234.5-35.degree., [.alpha.]<sub>D</sub> 252.degree. (c 1, H<sub>2</sub>O). l-IV (8.3 g.), 40 cc. dry dioxane, 20 cc. dry Me<sub>2</sub>CO, and 8 cc. Et<sub>3</sub>N treated in the usual manner with 6.8 g. ClCO<sub>2</sub>CH<sub>2</sub>CHMe<sub>2</sub> in 10 cc. dioxane and 10.8 g. II and 8 cc. Et<sub>3</sub>N in 50 cc. H<sub>2</sub>O and the mixt. worked up in the usual manner gave 9.5 l-VII, decompd. at 238-9.degree., [.alpha.]<sub>D</sub> 218.degree. (c 1, H<sub>2</sub>O), also obtained by extensive recrystn. of VII from aq. BuOH.

IT **123080-33-1**, 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-(2-benzoyl-4-methoxyphenoxy)propionamido]-3,3-dimethyl-7-oxo-, potassium salt (prepn. of)

RN 123080-33-1 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-(2-benzoyl-4-methoxyphenoxy)propionamido]-3,3-dimethyl-7-oxo-, potassium salt (6CI) (CA INDEX NAME)

Absolute stereochemistry.




● K

Same as #12

L4 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1960:104724 CAPLUS  
 DN 54:104724  
 OREF 54:19964a-c  
 TI Structure-activity relations in a series of synthetic penicillins  
 AU Gourevitch, A.; Hunt, G. A.; Lein, J.  
 CS Bristol Labs., Syracuse, NY  
 SO Antibiotics and Chemotherapy (Washington, D. C.) (1960), 10, 121-8  
 CODEN: ANTCAO; ISSN: 0570-3123  
 DT Journal  
 LA Unavailable  
 AB Min. inhibitory concn. against sensitive and resistant strains of Staphylococcus aureus and the curative dose for an acute infection produced in mice by S. aureus was detd. for 25 partially synthetic penicillins in the .alpha.-aryloxyalkyl series derived from 6-aminopenicillamic acid. The series have the general structure  $\text{Me}(\text{CH}_2)_n\text{CH}(\text{OAr})\text{CONHCH.C}(\text{:O}).\text{N.CH.S.CMe}_2.\text{CHCO}_2\text{H}$ , where n varied from 0 to 3; Ar = phenyl or substituted phenyl groups. Increasing side chain length resulted in decreased activity. In C.D.50 tests an over-all correlation between mol. wt. of the side chain and the amt. of serum binding was found. There was correlation between the min. inhibitory concn. in 50% serum and the C.D.50. .alpha.-Phenoxyethylpenicillin was the most active compd. tested.  
 IT **104218-05-5**, 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-[2-benzoyl-4-(p-methoxyphenoxy)phenoxy]propionamido]-3,3-dimethyl-7-oxo- (bactericidal action of)  
 RN 104218-05-5 CAPLUS  
 CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-[2-benzoyl-4-(p-methoxyphenoxy)phenoxy]propionamido]-3,3-dimethyl-7-oxo- (6CI) (CA INDEX NAME)

Absolute stereochemistry.



=&gt; file caold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

76.54

232.59

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-11.09

-11.09

FILE 'CAOLD' ENTERED AT 17:47:59 ON 06 FEB 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=&gt; d his

(FILE 'HOME' ENTERED AT 17:45:50 ON 06 FEB 2004)

FILE 'REGISTRY' ENTERED AT 17:45:55 ON 06 FEB 2004

L1 STRUCTURE UPLOADED

L2 25 S L1 SSS SAM

L3 439 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 17:47:07 ON 06 FEB 2004

L4 16 S L3

FILE 'CAOLD' ENTERED AT 17:47:59 ON 06 FEB 2004


=&gt; s l3

L5 3 L3

=&gt; d l5 1-3 bib,hitstr

L5 ANSWER 1 OF 3 CAOLD COPYRIGHT 2004 ACS on STN  
 AN CA57:15247i CAOLD  
 TI constitution and antibacterial action of semisynthetic  
 phenoxyalkylpenicillins and related compds.  
 AU Bauer, Klaus; Dillenburg, R.; Koenig, H. B.; Knott, T.; Meiser, W.; Offe,  
 H. A.; Schmid, J.; Schawartz, J.; Timmler, H.  
 TI varnish resins from diureas, HCHO, and alcs.  
 PA Badische Anilin- & Soda-Fabrik A.-G.  
 DT Patent  
 IT 98542-38-2  
 RN 98542-38-2 CAOLD  
 CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-(2-benzoyl-4-  
 chlorophenoxy)butyramido]-3,3-dimethyl-7-oxo- (7CI) (CA INDEX NAME)


Absolute stereochemistry.



*Same as #12*

L5 ANSWER 2 OF 3 CAOLD COPYRIGHT 2004 ACS on STN  
AN CA55:5470f CAOLD  
TI derivs. of 6-aminopenicillanic acid - (I) partially synthetic penicillins  
prepd. from .alpha.-aryloxyalkanoic acids  
AU Perron, Yvon G.; Minor, W. F.; Holdrege, C. T.; Gottstein, W. J.; Godfrey,  
J. C.; Crast, L. B.; Babel, R. B.; Cheney, L. C.  
IT 123080-33-1  
RN 123080-33-1 CAOLD  
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-(2-benzoyl-4-  
methoxyphenoxy)propionamido]-3,3-dimethyl-7-oxo-, potassium salt (6CI)  
(CA INDEX NAME)


Absolute stereochemistry.



● K

L5 ANSWER 3 OF 3 CAOLD COPYRIGHT 2004 ACS on STN  
AN CA54:19964b CAOLD  
TI structure-activity relations in a series of synthetic penicillins  
AU Gourevitch, Alexander; Hunt, G. A.; Lein, J.  
IT 104218-05-5  
RN 104218-05-5 CAOLD  
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-[2-benzoyl-4-(p-methoxyphenoxy)phenoxy]propionamido]-3,3-dimethyl-7-oxo- (6CI) (CA INDEX NAME)

Absolute stereochemistry.



10/070,084

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

8.61

241.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-11.09

STN INTERNATIONAL LOGOFF AT 17:48:24 ON 06 FEB 2004